Drugs Made In America Acquisition Corp
DMAA10.380USD
+0.020+0.19%
交易中 （美東）報價延遲15分鐘
347.89M總市值
94.62本益比TTM
關於 Drugs Made In America Acquisition Corp 公司
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition Corp簡介
公司代碼DMAA
公司名稱Drugs Made In America Acquisition Corp
上市日期Jan 28, 2025
CEOStockwell (Lynn)
員工數量- -
證券類型Ordinary Share
年結日Jan 28
公司地址1 East Broward Boulevard
城市FT LAUDERDALE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33301
電話19548703099
網址
公司代碼DMAA
上市日期Jan 28, 2025
CEOStockwell (Lynn)
Drugs Made In America Acquisition Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
其他
49.03%
持股股東
持股股東
佔比
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
其他
49.03%
股東類型
持股股東
佔比
Hedge Fund
30.25%
Corporation
25.57%
Investment Advisor/Hedge Fund
24.75%
Investment Advisor
5.74%
Research Firm
5.62%
Individual Investor
1.19%
其他
6.88%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
47
22.21M
67.76%
-8.45K
2025Q3
47
22.22M
67.76%
+1.02M
2025Q2
38
21.21M
54.90%
+2.81M
2025Q1
25
18.33M
0.00%
+18.33M
2024Q4
5
4.59M
15.73%
+4.59M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Drugs Made In America Acquisition LLC
8.57M
25.57%
+4.38M
+104.63%
Feb 25, 2025
Karpus Investment Management
2.74M
8.19%
+420.07K
+18.08%
Jun 30, 2025
First Trust Capital Management L.P.
2.24M
6.69%
+175.80K
+8.51%
Jun 30, 2025
Polar Asset Management Partners Inc.
1.90M
5.67%
--
--
Jun 30, 2025
Glazer Capital, LLC
1.82M
5.44%
-502.00
-0.03%
Jun 30, 2025
Westchester Capital Management, LLC
1.67M
4.98%
+690.00K
+70.48%
Jun 30, 2025
Hudson Bay Capital Management LP
1.80M
5.37%
--
--
Jun 30, 2025
Wolverine Asset Management, LLC
1.02M
3.05%
+418.87K
+69.46%
Jun 30, 2025
Mizuho Securities USA, LLC.
919.79K
2.74%
+919.79K
--
Jun 30, 2025
Aristeia Capital, L.L.C.
881.72K
2.63%
-18.28K
-2.03%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
CrossingBridge Pre-Merger SPAC ETF
0%
CrossingBridge Pre-Merger SPAC ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Drugs Made In America Acquisition Corp的前五大股東是誰？
Drugs Made In America Acquisition Corp的前五大股東如下：
Drugs Made In America Acquisition LLC持有股份：8.57M佔總股份比例：25.57%。
Karpus Investment Management持有股份：2.74M佔總股份比例：8.19%。
First Trust Capital Management L.P.持有股份：2.24M佔總股份比例：6.69%。
Polar Asset Management Partners Inc.持有股份：1.90M佔總股份比例：5.67%。
Glazer Capital, LLC持有股份：1.82M佔總股份比例：5.44%。
Drugs Made In America Acquisition LLC持有股份：8.57M佔總股份比例：25.57%。
Karpus Investment Management持有股份：2.74M佔總股份比例：8.19%。
First Trust Capital Management L.P.持有股份：2.24M佔總股份比例：6.69%。
Polar Asset Management Partners Inc.持有股份：1.90M佔總股份比例：5.67%。
Glazer Capital, LLC持有股份：1.82M佔總股份比例：5.44%。
Drugs Made In America Acquisition Corp的前三大股東類型是什麼？
Drugs Made In America Acquisition Corp 的前三大股東類型分別是：
Drugs Made In America Acquisition LLC
Karpus Investment Management
First Trust Capital Management L.P.
Drugs Made In America Acquisition LLC
Karpus Investment Management
First Trust Capital Management L.P.
有多少機構持有Drugs Made In America Acquisition Corp(DMAA)的股份？
截至2025Q4，共有47家機構持有Drugs Made In America Acquisition Corp的股份，合計持有的股份價值約為22.21M，占公司總股份的67.76% 。與2025Q3相比，機構持股有所增加，增幅為--。
哪個業務部門對Drugs Made In America Acquisition Corp的收入貢獻最大？
在--，--業務部門對Drugs Made In America Acquisition Corp的收入貢獻最大，創收--，占總收入的--% 。
